Zolbetuximab

MCE 國(guó)際站：Zolbetuximab

CAS：1496553-00-4

品牌：MedChemExpress (MCE)

存儲(chǔ)條件：Please store the product under the recommended conditions in the Certificate of Analysis.

生物活性： Zolbetuximab (IMAB362) 是一種靶向Claudin-18.2 的單克隆抗體。 Zolbetuximab 通過免疫效應(yīng)機(jī)制介導(dǎo) Claudin-18.2 陽性細(xì)胞的特異性殺傷。 Zolbetuximab可用于胃腸道腺癌和胰腺腫瘤的研究^[1]。

體外：Zolbetuximab (0-100 μg/mL) 與 CLDN18.2+ PC 細(xì)胞結(jié)合，誘導(dǎo)抗體依賴性細(xì)胞毒性 (ADCC) 和補(bǔ)體依賴性細(xì)胞毒性 (CDC)[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

體內(nèi)：單獨(dú)使用 Zolbetuximab (200 μg，靜脈注射) 以及與 Gemcitabine (HY-17026) (50 mg/kg，腹腔注射) 聯(lián)合使用，在小鼠 BxPC-3-CLDN18.2 異種移植模型中表現(xiàn)出抗腫瘤活性[2]。 Zolbetuximab (5.7 mg/kg，腹腔注射，每周 3 次，持續(xù)五周) 抑制 SNU-620 細(xì)胞異種移植模型中的腫瘤生長(zhǎng)[3]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: mouse BxPC-3-CLDN18.2, MIA PaCa-2-CLDN18.2 xenograft model[2] Dosage: 200 μg alone or with 50 mg/kg Gemcitabine Administration: i.v.; i.p. (Gemcitabine) Result: Inhibited tumor growth in two models, and prevented lung metastasis formation. Prolonged survival time, and lowered fractions of CLDN18.2+ cells in MIA PaCa-2-CLDN18.2 xenograft. Clinical Trial

熱賣產(chǎn)品：NMS-P715  | Aderbasib  | ZD-4190  | Donepezil  | Muscone  | WM-1119  | Glycochenodeoxycholic acid (sodium salt)  | CL075  | Ligustroflavone  | Envafolimab

研究領(lǐng)域：Others

作用靶點(diǎn)：Others

熱門產(chǎn)品線：重組蛋白  |  化合物庫  |  天然產(chǎn)物  |  熒光染料  |  PROTAC  |  同位素標(biāo)記物  |  寡核苷酸

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

參考文獻(xiàn)：

[1]. Kyuno D, et, al. Claudin-18.2 as a therapeutic target in cancers: cumulative findings from basic research and clinical trials. Tissue Barriers. 2022 Jan 2;10(1):1967080.[2]. Türeci ?, et al. Characterization of zolbetuximab in pancreatic cancer models. Oncoimmunology. 2018 Nov 10;8(1):e1523096. [3]. Zhong W, et al. Development of a Humanized VHH Based Recombinant Antibody Targeting Claudin 18.2 Positive Cancers. Front Immunol. 2022 Jun 28;13:885424.